Novartis Backs Alnylam and RNAi
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 64 (Table of Contents)
Published: 5 Oct-2005
DOI: 10.3833/pdr.v2005.i64.619 ISSN: 1756-7874
Section: General
Fulltext:
Abstract
Novartis adopted RNAi as a therapeutic platform by forming a strategic alliance with Alnylam Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS